Q3 EPS Estimates for Gossamer Bio Boosted by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for shares of Gossamer Bio in a research report issued on Thursday, March 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2026 earnings at ($0.20) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at ($0.07) EPS.

GOSS has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. Barclays lowered shares of Gossamer Bio from an “overweight” rating to an “underweight” rating in a research note on Tuesday, February 24th. Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th. Oppenheimer lowered their price objective on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. Finally, The Goldman Sachs Group cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.43.

Gossamer Bio Stock Down 6.5%

Shares of NASDAQ GOSS opened at $0.42 on Monday. Gossamer Bio has a fifty-two week low of $0.33 and a fifty-two week high of $3.87. The firm’s 50-day simple moving average is $1.65 and its 200 day simple moving average is $2.45. The stock has a market cap of $99.14 million, a P/E ratio of -0.56 and a beta of 2.09.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 351.49%.The business had revenue of $13.80 million for the quarter, compared to analyst estimates of $7.53 million.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors and hedge funds have recently bought and sold shares of GOSS. MMA Asset Management LLC bought a new position in shares of Gossamer Bio during the 4th quarter valued at about $31,000. Soltis Investment Advisors LLC bought a new stake in shares of Gossamer Bio in the 4th quarter worth approximately $31,000. Ciovacco Capital Management LLC acquired a new stake in Gossamer Bio during the third quarter valued at approximately $27,000. Beacon Pointe Advisors LLC acquired a new position in Gossamer Bio in the fourth quarter worth approximately $34,000. Finally, Ieq Capital LLC acquired a new stake in shares of Gossamer Bio during the 4th quarter valued at $35,000. 81.23% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Gossamer Bio

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $5.00 price target on GOSS, which provides a clear upside reference for investors relative to the current share price. HC Wainwright note (coverage)
• Positive Sentiment: The same HC Wainwright updates included upward revisions to some near‑term/near‑midterm estimates (notably FY2026 and FY2028 and a modest lift to Q3 2026 EPS), which suggests the analyst sees better operating/financial performance versus prior forecasts. HC Wainwright estimates update
• Neutral Sentiment: HC Wainwright’s changes are mixed overall — while some years were improved, FY2027 and FY2029 estimates were trimmed, leaving guidance directionally uncertain despite the maintained Buy rating. HC Wainwright mixed revisions
• Negative Sentiment: Levi & Korsinsky has opened a shareholder investigation alleging potential federal securities‑law violations related to Gossamer’s lead program (seralutinib) and the pivotal PROSERA Phase 3 trial — this raises legal and disclosure risk and typically weighs on the stock until details are resolved. Shareholders Alert: Investigation Into Gossamer Bio, Inc. (GOSS)

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.